Willingness to pay for a quality-adjusted life year: in search of a standard - PubMed

Review

Willingness to pay for a quality-adjusted life year: in search of a standard

R A Hirth et al. Med Decis Making. 2000 Jul-Sep.

Abstract

Cost-benefit analysis (CBA) provides a clear decision rule: undertake an intervention if the monetary value of its benefits exceed its costs. However, due to a reluctance to characterize health benefits in monetary terms, users of cost-utility and cost-effectiveness analyses must rely on arbitrary standards (e.g., < $50,000 per QALY) to deem a program "cost-effective." Moreover, there is no consensus regarding the appropriate dollar value per QALY gained upon which to base resource allocation decisions. To address this, the authors determined the value of a QALY as implied by the value-of-life literature and compared this value with arbitrary thresholds for cost-effectiveness that have come into common use. A literature search identified 42 estimates of the value of life that were appropriate for inclusion. These estimates were classified by method: human capital (HK), contingent valuation (CV), revealed preference/job risk (RP-JR) and revealed preference/non-occupational safety (RP-S), and by U.S. or non-U.S. origin. After converting these value-of-life estimates to 1997 U.S. dollars, the life expectancy of the study population, age-specific QALY weights, and a 3% real discount rate were used to calculate the implied value of a QALY. An ordinary least-squares regression of the value of a QALY on study type and national origin explained 28.4% of the variance across studies. Most of the explained variance was attributable to study type; national origin did not significantly affect the values. Median values by study type were $24,777 (HK estimates), $93,402 (RP-S estimates), $161,305 (CV estimates), and $428,286 (RP-JR estimates). With the exception of HK, these far exceed the "rules of thumb" that are frequently used to determine whether an intervention produces an acceptable increase in health benefits in exchange for incremental expenditures.

Similar articles

• Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

  Shepherd J, Jones J, Takeda A, Davidson P, Price A. Shepherd J, et al. Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047 Review.

• Estimating the monetary value of health: why and how.

  Himmler S. Himmler S. In: Kohlhammer VW, author. Schildmann J, Buch C, Zerth J, editors. Defining the Value of Medical Interventions: Normative and Empirical Challenges [Internet]. Stuttgart (DE): W. Kohlhammer GmbH; 2021. In: Kohlhammer VW, author. Schildmann J, Buch C, Zerth J, editors. Defining the Value of Medical Interventions: Normative and Empirical Challenges [Internet]. Stuttgart (DE): W. Kohlhammer GmbH; 2021. PMID: 36256794 Free Books & Documents. Review.

• Resource allocation in decision support frameworks.

  Phelps C, Madhavan G. Phelps C, et al. Cost Eff Resour Alloc. 2018 Nov 9;16(Suppl 1):48. doi: 10.1186/s12962-018-0128-5. eCollection 2018. Cost Eff Resour Alloc. 2018. PMID: 30455607 Free PMC article.

• A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.

  Mavrodi A, Aletras V. Mavrodi A, et al. Value Health Reg Issues. 2020 Sep;22:36-43. doi: 10.1016/j.vhri.2020.03.002. Epub 2020 Jul 27. Value Health Reg Issues. 2020. PMID: 32731168

Cited by

• An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness.

  Murphy SM, McDonell MG, McPherson S, Srebnik D, Angelo F, Roll JM, Ries RK. Murphy SM, et al. Drug Alcohol Depend. 2015 Aug 1;153:293-9. doi: 10.1016/j.drugalcdep.2015.05.004. Epub 2015 May 14. Drug Alcohol Depend. 2015. PMID: 26026494 Free PMC article. Clinical Trial.

• The role of funding and policies on innovation in cancer drug development.

  Kanavos P, Sullivan R, Lewison G, Schurer W, Eckhouse S, Vlachopioti Z. Kanavos P, et al. Ecancermedicalscience. 2010;4:164. doi: 10.3332/ecancer.2010.164. Epub 2010 Feb 3. Ecancermedicalscience. 2010. PMID: 22276026 Free PMC article. No abstract available.

• Reimbursement policies in the Asia-Pacific for chronic hepatitis B.

  Lim SG, Amarapurkar DN, Chan HL, Crawford DH, Gane EJ, Han KH, Ahn SH, Jafri W, Jia J, Kao JH, Lesmana LA, Lesmana CR, Mohamed R, Phiet PH, Piratvisuth T, Sarin SK, Sollarno JD, Eguchi Y, Mahtab MA, Lee KH. Lim SG, et al. Hepatol Int. 2015 Jan;9(1):43-51. doi: 10.1007/s12072-014-9593-x. Epub 2014 Dec 11. Hepatol Int. 2015. PMID: 25788378

• Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review.

  Padula WV, Chen HH, Phelps CE. Padula WV, et al. Appl Health Econ Health Policy. 2021 Mar;19(2):155-162. doi: 10.1007/s40258-020-00606-4. Appl Health Econ Health Policy. 2021. PMID: 32812212 Free PMC article.

• Concussion and football: a review and editorial.

  Abdullah KG, Grady MS, Levine JM. Abdullah KG, et al. Curr Neurol Neurosci Rep. 2015 Apr;15(4):11. doi: 10.1007/s11910-015-0535-3. Curr Neurol Neurosci Rep. 2015. PMID: 25702047 Review.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon